Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet’s Disease
Hand-out
Press Releases
November 14, 2024

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet’s Disease

Study DUS-AUBD-01 opens patient enrollment

bradford

The Bradford Era

Local & Social